Apotex gets Health Canada approval for Neulasta biosimilar
Health Canada has approved the world’s first Neulasta biosimilar, Lapelga (pegfilgrastim). Apotex, whose Apobiologix division received the approval, said that Lapelga would be its second biosimilar after its launch of Grastofil (filgrastim) in Canada in March 2016. The approval marks the first in a highly regulated market worldwide, the company said.
“Biosimilars provide an opportunity for the sustainability of global healthcare systems by increasing competition and reducing costs, and very importantly, giving patients increased access to highly effective and often lifesaving biological drugs,” said Klaus Martin, president of Apobiologix.
Citing IQVIA and Evaluate Pharma reports, Apotex noted that the global biologics market is set to reach more than $325 billion by 2022.
“Biosimilars provide an opportunity for the sustainability of global healthcare systems by increasing competition and reducing costs, and very importantly, giving patients increased access to highly effective and often lifesaving biological drugs,” said Klaus Martin, president of Apobiologix.
Citing IQVIA and Evaluate Pharma reports, Apotex noted that the global biologics market is set to reach more than $325 billion by 2022.